169 related articles for article (PubMed ID: 31997539)
1. Cost-effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration.
Witte K; Hasenfuss G; Kloppe A; Burkhoff D; Green M; Moss J; Peel A; Mealing S; Durand Zaleski I; Cowie MR
ESC Heart Fail; 2019 Dec; 6(6):1178-1187. PubMed ID: 31997539
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
5. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the ventricular assist device programme in the UK.
Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C
Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
Shah D; Lu X; Paly VF; Tsintzos SI; May DM
J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
[No Abstract] [Full Text] [Related]
9. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis.
Taylor RS; Sadler S; Dalal HM; Warren FC; Jolly K; Davis RC; Doherty P; Miles J; Greaves C; Wingham J; Hillsdon M; Abraham C; Frost J; Singh S; Hayward C; Eyre V; Paul K; Lang CC; Smith K
Eur J Prev Cardiol; 2019 Aug; 26(12):1252-1261. PubMed ID: 30884975
[TBL] [Abstract][Full Text] [Related]
10. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
Anker SD; Borggrefe M; Neuser H; Ohlow MA; Röger S; Goette A; Remppis BA; Kuck KH; Najarian KB; Gutterman DD; Rousso B; Burkhoff D; Hasenfuss G
Eur J Heart Fail; 2019 Sep; 21(9):1103-1113. PubMed ID: 30652394
[TBL] [Abstract][Full Text] [Related]
11. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
[TBL] [Abstract][Full Text] [Related]
15. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study.
Wiegn P; Chan R; Jost C; Saville BR; Parise H; Prutchi D; Carson PE; Stagg A; Goldsmith RL; Burkhoff D
Circ Heart Fail; 2020 Apr; 13(4):e006512. PubMed ID: 32264716
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.
Abraham WT; Kuck KH; Goldsmith RL; Lindenfeld J; Reddy VY; Carson PE; Mann DL; Saville B; Parise H; Chan R; Wiegn P; Hastings JL; Kaplan AJ; Edelmann F; Luthje L; Kahwash R; Tomassoni GF; Gutterman DD; Stagg A; Burkhoff D; Hasenfuß G
JACC Heart Fail; 2018 Oct; 6(10):874-883. PubMed ID: 29754812
[TBL] [Abstract][Full Text] [Related]
19. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
